AstraZeneca’s Antibody Favorable in RSV in Phase 2/3 Trial,

… nirsevimab, demonstrated positive safety and tolerability profile in infants at high risk of respiratory syncytial virus (RSV) in a Phase 2/3 clinical trial., … nirsevimab, demonstrated positive safety and tolerability profile in infants at high risk of respiratory syncytial virus (RSV) in a Phase 2/3 clinical trial., Read More

Scroll to Top